Respiratory tract exacerbations revisited: Ventilation, inflammation, perfusion, and structure (VIPS) monitoring to redefine treatment

Pediatric Pulmonology

Volumn 50, Issue , 2015, Pages S57-S65

  Tiddens, Harm A W M ^a,b   Stick, Stephen M ^c,d   Wild, Jim M ^e   Ciet, Pierluigi ^a,b   Parker, Geoffrey J M ^f,g   Koch, Armin ^h   Vogel Claussen, Jens ^h  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g Bioxydyn Limited   (United Kingdom)

^h HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

lung disease; magnetic resonance imaging; pathobiology

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; MUCOLYTIC AGENT; OXYGEN;

AIRWAY OBSTRUCTION; ANTIBIOTIC THERAPY; BREATHING EXERCISE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYSTIC FIBROSIS; DISEASE EXACERBATION; EXPIRED AIR; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CLEARANCE; LUNG FLUID; LUNG FUNCTION TEST; LUNG PERFUSION; LUNG STRUCTURE; LUNG VENTILATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RESPIRATORY TRACT EXACERBATION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SCORING SYSTEM; SPIROMETRY; ADOLESCENT; ADULT; AGED; BREATHING; CHEMISTRY; CHILD; COMPLICATION; DISEASE COURSE; INFLAMMATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PERFUSION; PHYSIOLOGIC MONITORING; PROCEDURES; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; LUNG; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MONITORING, PHYSIOLOGIC; OXYGEN; PERFUSION; RESPIRATION; RESPIRATORY TRACT INFECTIONS; SPIROMETRY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941087623     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23266     Document Type: Review

References (45)

1. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F,. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012; 40: 61-66.
2. de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, et al., Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011; 66: 680-685.
3. Byrnes CA, Vidmar S, Cheney JL, Carlin JB, Armstrong DS, Cooper PJ, et al., Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. Thorax 2013; 68: 643-651.
4. Bilton D, Canny G, Conway S, Dumcius S, Hjelte L, Proesmans M, et al., Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros 2011; 10 (Suppl 2) S79-S81.
5. Gangell CL, Shackleton C, Poreddy S, Kappers J, Gaydon JE, Sloots TP, et al., Feasibility of parental collected nasal swabs for virus detection in young children with cystic fibrosis. J Cyst Fibros 2014; 13: 661-666.
6. Hurley MN, Ariff AH, Bertenshaw C, Bhatt J, Smyth AR,. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J Cyst Fibros 2012; 11: 288-292.
7. Robinson PD, Cooper P, Van Asperen P, Fitzgerald D, Selvadurai H,. Using index of ventilation to assess response to treatment for acute pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2009; 44: 733-742.
8. Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, Aziz ZA, et al., Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 2013; 68: 532-539.
9. Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ, Jr,. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010; 182: 1137-1143.
10. Bhatt JM,. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 2013; 22 205-216.
11. Vermeulen F, Proesmans M, Boon M, Havermans T, De Boeck K,. Lung clearance index predicts pulmonary exacerbations in young patients with cystic fibrosis. Thorax 2014; 69: 39-45.
12. Welsh L, Nesci C, Tran H, Tomai M, Ranganathan S,. Lung clearance index during hospital admission in school-age children with cystic fibrosis. J Cyst Fibros 2014; 13: 687-691.
13. Waters VJ, Stanojevic S, Sonneveld N, Klingel M, Grasemann H, Yau YC, et al., Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros 2015; Feb 14. pii: S1569-1993(15) 00009-0. DOI: 10.1016/j.jcf.2015.01.007. [Epub ahead of print].
14. Parkins MD, Rendall JC, Elborn JS,. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012; 141: 485-493.
15. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH,. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 627-632.
16. Loeve M, Hop WC, de Bruijne M, van Hal PT, Robinson P, Aitken ML, et al., Chest Computed Tomography Scores Are Predictive of Survival in Patients with Cystic Fibrosis Awaiting Lung Transplantation. Am J Respir Crit Care Med 2012; 185: 1096-1103.
17. Klein M, Cohen-Cymberknoh M, Armoni S, Shoseyov D, Chisin R, Orevi M, et al., 18F-fluorodeoxyglucose-PET/CT imaging of lungs in patients with cystic fibrosis. Chest 2009; 136: 1220-1228.
18. Amin R, Charron M, Grinblat L, Shammas A, Grasemann H, Graniel K, et al., Cystic fibrosis: detecting changes in airway inflammation with FDG PET/CT. Radiology 2012; 264: 868-875.
19. Chen DL, Atkinson JJ, Ferkol TW,. FDG PET imaging in cystic fibrosis. Semin Nucl Med. 2013; 43: 412-419.
20. Brown JS, Zeman KL, Bennett WD,. Regional deposition of coarse particles and ventilation distribution in healthy subjects and patients with cystic fibrosis. J Aerosol Med. 2001; 14: 443-454.
21. Woodhouse N, Wild JM, van Beek EJ, Hoggard N, Barker N, Taylor CJ,. Assessment of hyperpolarized 3He lung MRI for regional evaluation of interventional therapy: a pilot study in pediatric cystic fibrosis. J Magn Reson Imaging 2009; 30: 981-988.
22. Sun Y, O'Sullivan BP, Roche JP, Walvick R, Reno A, Baker D, et al., Using hyperpolarized 3He MRI to evaluate treatment efficacy in cystic fibrosis patients. J Magn Reson Imaging 2011; 34: 1206-1211.
23. Bauman G, Puderbach M, Heimann T, Kopp-Schneider A, Fritzsching E, Mall MA, et al., Validation of Fourier decomposition MRI with dynamic contrast-enhanced MRI using visual and automated scoring of pulmonary perfusion in young cystic fibrosis patients. Eur J Radiol 2013; 82: 2371-2377.
24. Davis S, Fordham LA, Brody AS, Noah TL, Retsch-Bogart GZ, Qaqish BF, et al., Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 943-950.
25. Cantin AM, Hartl D, Konstan MW, Chmiel JF,. Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. J Cyst Fibros 2015; 14: 419-430.
26. Shoki AH, Mayer-Hamblett N, Wilcox PG, Sin DD, Quon BS,. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest 2013; 144: 1659-1670.
27. Wojewodka G, De Sanctis JB, Bernier J, Berube J, Ahlgren HG, Gruber J, et al., Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients. PLoS ONE 2014; 9: e88567.
28. Sagel SD, Thompson V, Chmiel JF, Montgomery GS, Nasr SZ, Perkett E, et al., Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation. Ann Am Thorac Soc 2015; 12: 708-717.
29. Zhang WJ, Niven RM, Young SS, Liu YZ, Parker GJ, Naish JH,. Dynamic oxygen-enhanced magnetic resonance imaging of the lung in asthma-initial experience. Eur J Radiol 2015; 84: 318-326.
30. Vogel-Claussen J, Renne J, Hinrichs J, Schonfeld C, Gutberlet M, Schaumann F, et al., Quantification of pulmonary inflammation after segmental allergen challenge using turbo-inversion recovery-magnitude magnetic resonance imaging. Am J Respir Crit Care Med 2014; 189: 650-657.
31. Renne J, Hinrichs J, Schonfeld C, Gutberlet M, Winkler C, Faulenbach C, et al., Noninvasive quantification of airway inflammation following segmental allergen challenge with functional MR imaging: a proof of concept study. Radiology 2015; 274: 267-275.
32. Mott LS, Park J, Murray CP, Gangell CL, de Klerk NH, Robinson PJ, et al., Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012; 67: 509-516.
33. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J, Fleischner society: Glossary of terms for thoracic imaging. Radiology 2008; 246: 697-722.
34. Wielputz MO, Puderbach M, Kopp-Schneider A, Stahl M, Fritzsching E, Sommerburg O, et al., Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2014; 189: 956-965.
35. Loeve M, Rosenow T, Gorbunova V, Hop WC, Tiddens HA, de Bruijne M,. Reversibility of trapped air on chest computed tomography in cystic fibrosis patients. Eur J Radiol 2015; 84: 1184-1190.
36. Hueper K, Parikh MA, Prince MR, Schoenfeld C, Liu C, Bluemke DA, et al., Quantitative and semiquantitative measures of regional pulmonary microvascular perfusion by magnetic resonance imaging and their relationships to global lung perfusion and lung diffusing capacity: the multiethnic study of atherosclerosis chronic obstructive pulmonary disease study. Invest Radiol 2013; 48: 223-230.
37. Schonfeld C, Cebotari S, Voskrebenzev A, Gutberlet M, Hinrichs J, Renne J, et al., Performance of perfusion-weighted Fourier decomposition MRI for detection of chronic pulmonary emboli. J Magn Reson Imaging 2015; 42: 72-79.
38. Shah RM, Sexauer W, Ostrum BJ, Fiel SB, Friedman AC,. High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR. American Journal of Roentgenology 1997; 169: 375-380.
39. Kuo W, Ciet P, Tiddens HA, Zhang W, Guillerman RP, van Straten M,. Monitoring cystic fibrosis lung disease by computed tomography. Radiation risk in perspective. Am J Respir Crit Care Med 2014; 189: 1328-1336.
40. Willemink MJ, de Jong PA,. Pediatric chest computed tomography at a radiation dose approaching a chest radiograph. Am J Respir Crit Care Med 2013; 188: 626-627.
41. Dournes G, Grodzki D, Macey J, Girodet PO, Fayon M, Chateil JF, et al., Quiet submillimeter MR imaging of the lung is feasible with a PETRA sequence at 1.5 T. Radiology 2015; 276: 258-265.
42. Bakker EM, Volpi S, Salonini E, van der Wiel EC, Sintnicolaas C, Hop WCJ, et al., Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J 2011; 38: 1328-1335.
43. Asner S, Waters V, Solomon M, Yau Y, Richardson SE, Grasemann H, et al., Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 2012; 11: 433-439.
44. Sutanto EN, Kicic A, Foo CJ, Stevens PT, Mullane D, Knight DA, et al., Innate inflammatory responses of pediatric cystic fibrosis airway epithelial cells: Effects of nonviral and viral stimulation. Am J Respir Cell Mol Biol 2011; 44: 761-767.
45. Lam JC, Somayaji R, Surette MG, Rabin HR, Parkins MD,. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response. BMC Infect Dis 2015; 15: 145.